Regenmed Retatrutide 40mg
Regenmed Retatrutide 40mg
د.إ1,500.00 Original price was: د.إ1,500.00.د.إ1,350.00Current price is: د.إ1,350.00. Add to cart
Sale!

Regenmed Retatrutide 40mg

Original price was: د.إ1,500.00.Current price is: د.إ1,350.00.

-10%

Retatrutide is a triple agonist that activates the GLP-1, GIP, and glucagon receptors. It enhances insulin secretion, increases energy expenditure, and reduces appetite, resulting in significant improvements in weight loss and metabolic regulation.

10 in stock

🚚

SAME DAY DELIVERY
Order by 8PM in Dubai 🇦🇪

📦
Shipping Available
💬
24/7 Support
🔒
Discreet Packaging
🧪
Lab Tested

🔒
Guaranteed Safe Checkout

Secure Payment Methods

RegenMed · Verified Stock

Retatrutide 40mg Pre Loaded Pen

Triple agonist of GLP-1, GIP and Glucagon receptors. Supplied in a pharmaceutical grade pre loaded pen by RegenMed, third party tested by Janoshik Analytical at 99.676% purity.

What’s Included

40mg Retatrutide Pre Loaded Peptide Pen
Disposable Pen Needle Tips
Independent Lab Test
Janoshik Analytical Report
99.67%
HPLC Verified Purity
Task Number
#148782
Analysis Date
28 April 2026
Concentration
13.62 mg/ml
Purity
99.676%
Tests Requested
Common GLP-1 peptide blind test (Semaglutide, Tirzepatide and Retatrutide)
🔒 Independently Verifiable
Verify this test at www.janoshik.com/verify
Z5DMHQVBKX4Q

Inside the Vial · Reference Data

Compound Retatrutide (LY3437943)
Class Triple GIP / GLP-1 / Glucagon agonist
Formula C221H343N57O68
Molecular Weight ≈ 4731 g/mol
CAS Number 2381089-83-2
Purity 99.67% by HPLC
Storage Refrigerated 2°C to 8°C

How It Works

Three receptors. One molecule.

01 / 03

GLP-1 Receptor

Studied for glucose dependent insulin secretion and gastric emptying.

02 / 03

GIP Receptor

Linked to lipid handling and energy expenditure.

03 / 03

Glucagon Receptor

The pathway that sets retatrutide apart from dual agonists.

Sources

Cited, not claimed.

Every reference below is publicly available and peer reviewed.

23 2023
NEJM · Phase 2
Triple Hormone Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial
Jastreboff AM et al. · New England Journal of Medicine
23 2023
Lancet · Phase 2
Retatrutide for type 2 diabetes: a phase 2 trial
Rosenstock J et al. · The Lancet
24 2024
Nature Med · Phase 2A
Retatrutide for metabolic dysfunction associated steatotic liver disease
Sanyal AJ et al. · Nature Medicine
22 2022
Pharmacology
LY3437943: discovery to clinical proof of concept
Coskun T et al. · Cell Metabolism
🧊
Storage & Handling
Store the pre loaded pen in a refrigerator at 2°C to 8°C. Keep away from direct sunlight and freezing temperatures. Read the package leaflet before use.
Got Questions?
Message us on WhatsApp · 24/7 Support
💬 WhatsApp Us Now